Literature DB >> 23288424

Natural selection of adaptive mutations in non-structural genes increases trans-encapsidation of hepatitis C virus replicons lacking envelope protein genes.

Carole Fournier1,2, François Helle1, Véronique Descamps1,2, Virginie Morel1,2, Catherine François1,2, Sarah Dedeurwaerder3,1, Czeslaw Wychowski4, Gilles Duverlie1,2, Sandrine Castelain1,2.   

Abstract

A trans-packaging system for hepatitis C virus (HCV) replicons lacking envelope glycoproteins was developed. The replicons were efficiently encapsidated into infectious particles after expression in trans of homologous HCV envelope proteins under the control of an adenoviral vector. Interestingly, expression in trans of core or core, p7 and NS2 with envelope proteins did not enhance trans-encapsidation. Expression of heterologous envelope proteins, in the presence or absence of heterologous core, p7 and NS2, did not rescue single-round infectious particle production. To increase the titre of homologous, single-round infectious particles in our system, successive cycles of trans-encapsidation and infection were performed. Four cycles resulted in a 100-fold increase in the yield of particles. Sequence analysis revealed a total of 16 potential adaptive mutations in two independent experiments. Except for a core mutation in one experiment, all the mutations were located in non-structural regions mainly in NS5A (four in domain III and two near the junction with the NS5B gene). Reverse genetics studies suggested that D2437A and S2443T adaptive mutations, which are located at the NS5A-B cleavage site did not affect viral replication, but enhanced the single-round infectious particles assembly only in trans-encapsidation model. In conclusion, our trans-encapsidation system enables the production of HCV single-round infectious particles. This system is adaptable and can positively select variants. The adapted variants promote trans-encapsidation and should constitute a valuable tool in the development of replicon-based HCV vaccines.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23288424     DOI: 10.1099/vir.0.049676-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  8 in total

1.  Evasion of superinfection exclusion and elimination of primary viral RNA by an adapted strain of hepatitis C virus.

Authors:  Brian Webster; Melanie Ott; Warner C Greene
Journal:  J Virol       Date:  2013-10-02       Impact factor: 5.103

Review 2.  An insight into the diagnosis and pathogenesis of hepatitis C virus infection.

Authors:  Mohammad Irshad; Dhananjay Singh Mankotia; Khushboo Irshad
Journal:  World J Gastroenterol       Date:  2013-11-28       Impact factor: 5.742

Review 3.  Cellular and molecular targets for the immunotherapy of hepatocellular carcinoma.

Authors:  Vikrant Rai; Joe Abdo; Abdullah N Alsuwaidan; Swati Agrawal; Poonam Sharma; Devendra K Agrawal
Journal:  Mol Cell Biochem       Date:  2017-06-07       Impact factor: 3.842

Review 4.  Genetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine Design.

Authors:  Alexander W Tarr; Tanvi Khera; Kathrin Hueging; Julie Sheldon; Eike Steinmann; Thomas Pietschmann; Richard J P Brown
Journal:  Viruses       Date:  2015-07-17       Impact factor: 5.048

Review 5.  Incorporation of hepatitis C virus E1 and E2 glycoproteins: the keystones on a peculiar virion.

Authors:  Gabrielle Vieyres; Jean Dubuisson; Thomas Pietschmann
Journal:  Viruses       Date:  2014-03-11       Impact factor: 5.048

6.  Nanoparticle encapsidation of Flock house virus by auto assembly of Tobacco mosaic virus coat protein.

Authors:  Payal D Maharaj; Jyothi K Mallajosyula; Gloria Lee; Phillip Thi; Yiyang Zhou; Christopher M Kearney; Alison A McCormick
Journal:  Int J Mol Sci       Date:  2014-10-14       Impact factor: 5.923

7.  Hepatitis C Virus Resistance to Carbohydrate-Binding Agents.

Authors:  Laure Izquierdo; Catarina Oliveira; Carole Fournier; Véronique Descamps; Virginie Morel; Jean Dubuisson; Etienne Brochot; Catherine Francois; Sandrine Castelain; Gilles Duverlie; Francois Helle
Journal:  PLoS One       Date:  2016-02-12       Impact factor: 3.240

8.  Permissivity of primary human hepatocytes and different hepatoma cell lines to cell culture adapted hepatitis C virus.

Authors:  Francois Helle; Etienne Brochot; Carole Fournier; Véronique Descamps; Laure Izquierdo; Thomas W Hoffmann; Virginie Morel; Yves-Edouard Herpe; Abderrahmane Bengrine; Sandrine Belouzard; Czeslaw Wychowski; Jean Dubuisson; Catherine Francois; Jean-Marc Regimbeau; Sandrine Castelain; Gilles Duverlie
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.